Infliximab with Methotrexate (Crohn)

  Crohn, IBD

Infliximab with Methotrexate (Crohn)


Related articles (Crohn):
*
Azathioprine Crohn
*Methotrexate in Crohn
*Infliximab in Crohn (ACCENT I)
*Infliximab with Azathiopurine (Crohn)
*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)
*Adalimumab (CLASSIC & CHARM trial – Crohn)
*Adalimumab with immunomodulator (Crohn)
*Ustekinumab (UNITI trial – Crohn – 2016)
*Vedolizumab (GEMINI II – Crohn – 2013)


Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146(3):681‐688.e1. doi:10.1053/j.gastro.2013.11.024

Background & aims: Methotrexate and infliximab are effective therapies for Crohn’s disease (CD). In the combination of maintenance methotrexate-infliximab trial, we evaluated the potential superiority of combination therapy over infliximab alone.

Methods: In a 50-week, double-blind, placebo-controlled trial, we compared methotrexate and infliximab with infliximab alone in 126 patients with CD who had initiated prednisone induction therapy (15-40 mg/day) within the preceding 6 weeks. Patients were assigned randomly to groups given methotrexate at an initial weekly dose of 10 mg, escalating to 25 mg/week (n = 63), or placebo (n = 63). Both groups received infliximab (5 mg/kg of body weight) at weeks 1, 3, 7, and 14, and every 8 weeks thereafter. Prednisone was tapered, beginning at week 1, and discontinued no later than week 14. The primary outcome was time to treatment failure, defined as a lack of prednisone-free remission (CD Activity Index, <150) at week 14 or failure to maintain remission through week 50.

Results: Patients’ baseline characteristics were similar between groups. By week 50, the actuarial rate of treatment failure was 30.6% in the combination therapy group compared with 29.8% in the infliximab monotherapy group (P = .63; hazard ratio, 1.16; 95% confidence interval, 0.62-2.17). Prespecified subgroup analyses failed to show a benefit in patients with short disease duration or an increased level of C-reactive protein. No clinically meaningful differences were observed in secondary outcomes. Combination therapy was well tolerated.

Conclusions: The combination of infliximab and methotrexate, although safe, was no more effective than infliximab alone in patients with CD receiving treatment with prednisone. ClincialTrials.gov number, NCT00132899.

Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology. 2014;146(3):681‐688.e1. doi:10.1053/j.gastro.2013.11.024

References:

Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146(3):681‐688.e1. doi:10.1053/j.gastro.2013.11.024

LEAVE A COMMENT